Drug intelligence / Profile preview

recombinant RSV vaccine (CHO cell) with adjuvant suspension

Development stage: Unknown
Lead developer: Yikang Biotech
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The recombinant RSV vaccine (CHO cell) with adjuvant suspension is an investigational biological subunit vaccine candidate being developed by Yikang Biotech (Suzhou) Co., Ltd. in collaboration with Jiangsu Recbio Technology Co., Ltd. for the prevention of Respiratory Syncytial Virus (RSV) infection. The vaccine consists of a recombinant RSV fusion (F) glycoprotein stabilized in its prefusion conformation (preF), expressed using a Chinese Hamster Ovary (CHO) cell mammalian expression system. It is formulated with a novel adjuvant system developed by Jiangsu Recbio Technology to enhance immunogenicity and elicit robust neutralizing antibody and cellular immune responses. The vaccine is designed to prevent lower respiratory tract disease (LRTD) caused by RSV infection, particularly in older adults and other vulnerable populations. It is currently in Phase 1 clinical development in China.

Other names: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) (Adjuvanted)Recombinant RSV Vaccine (CHO Cell) (Adjuvanted)重组呼吸道合胞病毒疫苗（CHO细胞）（佐剂）

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on recombinant RSV vaccine (CHO cell) with adjuvant suspension.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant RSV vaccine (CHO cell) with adjuvant suspension.

Explore the full profile